Institute of Pathology, University of Bern, Bern, Switzerland.
Department of Medical Oncology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland.
Br J Cancer. 2020 Sep;123(5):700-708. doi: 10.1038/s41416-020-0954-z. Epub 2020 Jun 30.
Tumour budding in colorectal cancer has become an important prognostic factor. Represented by single cells or small tumour cell clusters at the invasion front of the tumour mass, these tumour buds seem to reflect cells in a 'hybrid' state of epithelial-mesenchymal transition, and evidence indicates that the presence of these entities is associated with lymph node metastasis, local recurrence and distant metastatic disease. The International Tumour Budding Consensus Conference (ITBCC) has highlighted a scoring system for the reporting of tumour budding in colorectal cancer, as well as different clinical scenarios that could affect patient management. Other organs are not spared: tumour budding has been described in numerous gastrointestinal and non-gastrointestinal cancers. Here, we give an update on ITBCC validation studies in the context of colorectal cancer and the clinical implications of tumour budding throughout the upper gastrointestinal and pancreatico-biliary tract.
结直肠癌的肿瘤出芽已成为一个重要的预后因素。肿瘤出芽以肿瘤块浸润前缘的单个细胞或小肿瘤细胞簇为代表，这些肿瘤出芽似乎反映了处于上皮-间充质转化“混合”状态的细胞，并且有证据表明这些实体的存在与淋巴结转移、局部复发和远处转移疾病有关。国际肿瘤出芽共识会议（ITBCC）强调了一种用于报告结直肠癌肿瘤出芽的评分系统，以及可能影响患者管理的不同临床情况。其他器官也不能幸免：在许多胃肠道和非胃肠道癌症中都描述了肿瘤出芽。在这里，我们根据结直肠癌的 ITBCC 验证研究以及上胃肠道和胰胆系统中肿瘤出芽的临床意义提供最新信息。
